Corporate Introduction
Yerlika Pharmaceutical Industry and Trade Inc. was established in November 2016 in Türkiye with the aim of producing biotechnological drugs and entering international markets. Our modern facility, located in the Çerkezköy Organized Industrial Zone, operates at world-class standards with advanced technology and a highly skilled team.
Our company specializes in the development and production of biotechnological drugs, offering both our own products and services as a CMO (Contract Manufacturing Organization) and CDMO (Contract Development and Manufacturing Organization) for other companies. With high-quality production standards and a customer-oriented approach, we are positioned as a reliable business partner in national and international markets.
With our modern infrastructure and strong R&D capabilities, we are focused on localizing biotechnological products and providing solutions for the treatment of cancer and rare diseases. Our state-of-the-art production facility operates in compliance with GMP (Good Manufacturing Practices) standards.
Brand Identity
Yerlika's brand identity combines the determination to deliver innovative solutions with the power of modern science. This identity, centered on scientific excellence and innovation, concretely reflects our ambition to be a pioneer in the field of biotechnology.
- Science and Innovation: Our approach to continuous improvement in healthcare and adoption of modern technology forms the cornerstone of our brand.
- Trust and Ethics: Commitment to ethical values and reliability are indispensable elements of our brand identity.
- Sustainability: Our eco-friendly and sustainable production processes reflect our responsibility towards the future.
Yerlika’s brand identity is not just a visual representation but also a testament to our commitment to customers, partners, and society. With our innovative spirit and scientific approach, we have established a strong identity in the biotechnology sector, and we carry this identity with pride.
Our Vision for the Future
At Yerlika, we are committed to realizing our goal of becoming a leader in biotechnology by adhering to the following core principles:
- Solutions That Transform Lives: We aim not only to develop products but also to offer innovative treatment methods that enhance quality of life.
- Localization of Biotechnological Products: We are increasing domestic production capacity to reduce our country’s dependency on imported biotechnological products.
- Innovation and Technology: By combining the wisdom of the past with modern science, we develop advanced, technology-driven solutions.
- Positioning Turkey as a Global Hub: We work with the vision of elevating our country to an international center in the fields of healthcare and biotechnology.
- Accessibility and Effectiveness: We are committed to offering more effective and accessible solutions by facilitating patient access to treatment.
Yerlika aims to maintain its innovative leadership in the healthcare sector by strengthening its presence in national and international markets through advanced technological infrastructure and a highly skilled team.
Our Vision
- Yerlika is steadfast in its journey to becoming a global leader in biotechnology. Our goal is to position Turkey as a hub for biotechnological drug production, shaping the healthcare industry with innovative solutions. By combining advanced technology with expertise, we deliver solutions that enhance the quality of life. Reliability, sustainability, and ethical values are the foundations of every step we take.
Our Mission
- For us, biotechnology is not just about producing drugs; it’s about improving lives and shaping the future. We are developing groundbreaking drugs for challenging conditions such as cancer, multiple sclerosis, blood disorders, and metabolic diseases. Our mission is to provide effective and accessible solutions by ensuring easier access to treatments for patients. Additionally, we aim to strengthen domestic production, making Turkey a self-reliant and influential country in this field. Through our environmentally friendly production processes, we care not only for today but also for the future.
Türkiye's Health, Türkiye's Wealth: Now Is the Time to Localize Biotechnological Drugs
2024
Completion of the first Contract Cartridge production
Acceptance of the TÜBİTAK Teydeb project on the development of two molecules
Start of Phase I Study for Adalimumab Biosimilar
Authorization application for three new biosimilar molecules2023
TMMDA GMP Certificate (7 molecules)
Initiation of contract process development studies for cancer gene therapy (original molecule)
Initiation of the localization project for three biological molecules2022
Completion of Two Monoclonal Antibody Filling Studies
Marketing Approval of Recombinant Factor VIIa biosimilar2021
TMMDA GMP Certificate (Two molecules)2019
R&D and Production Facility Establishment2016
Company Establishment